fbpx

Our Experience

Providing our partners with the expertise needed in order to conduct the highest quality research.

Contact Us
Vantage Clinical Trials has extensive experience and has built a trusting relationship with Pharmaceutical Sponsors and CROs throughout the years. We consistently meet enrollment goals, produce quality data and make the research process extremely efficient by bringing the expertise needed to conduct successful research.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24

  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35

  • 111
  • 333
  • 555
  • 666
  • 777
  • 999
  • 1010
  1. M04-697, A Phase 3, Randomized, Multicenter, Double-Blind Study Comparing the Analgesic Efficacy of Extended Release XXXX/XXXX Tablets XXXX to Placebo in Subjects with Osteoarthritis – 2006
  1. A55710/1038, A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessing the Safety and Efficacy of XXXX in the Prevention of Venous Thromboembolic Events (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement – 2006
  1. 3100N7-210-WW, A Phase 2/3 Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP2)/Calcium Phosphate Matrix (CPM) in closed Diaphyseal Tibial Fractures – 2006
  1. 3100N7-211-WW, A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard of Care Controlled, Feasibility and Safety Study of rhBMP-2-CPM as an Adjuvant Therapy for Fractures of the Proximal Femur – 2006
  1. 3100N7-212-WW, A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus – 2006
  1. 11355, Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE; a controlled, double-blind, randomized study of XXXX in the prevention of VTE in subjects undergoing elective total knee replacement – 2006
  1. A3241008-1013, A One-Year Follow-up Assessment of Subjects who Participated in Protocol A3241002 – 2006
  1. SMI05002, Survey to assess the prevalence, characteristics and impact of breakthrough pain in chronic pain patients with and without cancer managed by clinicians who are not pain specialists – 2006
  1. DU176b-PRT011, A Phase IIB, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose Study of XXX Compared to XXX in Patients Undergoing Elective Unilateral Total Hip Replacement – 2006
  1. C25608/3040/BP/US, An Open-Label, 12-month Study to Evaluate the Safety, Tolerability, and Efficacy or XXXX XXXX XXXX for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Noncancer Pain – 6 month extension study – 2006
  1. 2005-01D, A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of XXXXX for Treatment of Painful Osteoarthritis of the Knee, with an Open-Label Safety Extension, 2006
  1. 2006-02, A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of XXXXX for Treatment of Osteoarthritis (OA) of the First Carpometacarpal (CMC) Joint
  1. A3191331 Gastrointestinal (GI) Randomized event and safety open label NSAID study (GI-REASONS) A randomized, open-label, blinded-endpoint, parallel-group trial of GI safety of XXXX compared with non-selective nonsteroidal anti-inflammatory drugs (NSAIDS) in osteoarthritis patients. (2007)
  1. 150-CL-033 A Phase 2b, Double Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of XXXX In Subjects Undergoing Primary Elective Knee
    1. Arthroplasty (2008)
  1. WA2049A/ACT3985g A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of XXXX Compared Placebo in Patients with Active Rheumatoid Arthritis Continuing Methotrexate Treatment
  1. WA20496/ACT4394g A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of XXXX Given as a Single Infusion of Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
  1. KF5503/16: R331333-PAI-3014 A Randomized Withdrawal, Active and Placebo-Controlled, Double-Blind, Multicenter Phase III Trial Assessing Safety and Efficacy of Oral XXXX in Subjects with Moderate to Severe Chronic Malignant Tumor-Related Pain (2007)
  1. NMT 1077-301 A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release XXXX Compared to Placebo in Patients with Chronic Low Back Pain (2008)
  1. NMT 1077-302 A Phase III, Flexible-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release XXXX Compared to Placebo in Patients with Osteoarthritis Pain (2007)
  1. C0407 Multicenter, Open Label Extension Study of 8 mg XXXX in Subjects who completed Protocols C0405 or C0406 for Symptomatic Gout (2007)
  1. 01-06-TL-OPIMET-008 A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of XXXX and XXXX Fixed-Dose Combination Therapy Compared to XXXX and to XXXX in the Treatment of Subjects with Type 2 Diabetes (2007)
  1. TAK-442_201 A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX in Subjects Undergoing Total Knee Replacement (2007)
  1. 11355 BAYER RECORD 4 Study: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE; a Controlled, Double-Blind, Randomized Study of XXXX in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement (2006)
  1. 3100N7-210-WW A Phase II/III, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone XXXX in Closed Diaphyseal Tibial Fractures (2007)
  1. 3100N7-211-WW A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard of Care Controlled, Feasibility and Safety Study of XXXX as an Adjuvant Therapy for Fractures of the Proximal Femur (2007)
  1. 3100N7-212 A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of XXXX as an Adjuvant Therapy in Closed Fractures of the Humerus (2006)
  1. NU281 Effects of the Consumption of Plant Sterols-enriched Dairy Fermented Product on Hypercholesterolemia Management in Hypercholesterolemic Adults (2008)
  1. 150-CL-033 A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of XXXX in Subjects Undergoing Primary Elective Knee Arthroplasty (2007)
  1. 150-CL-033 A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of XXXX in Subjects Undergoing Primary Elective Knee Arthroplasty (2007)
  1. 150-CL-040 A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare XXXX bid and qd Doses and XXXX for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery (2009)
  1. A4091011 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of XXXX in Patients with Osteoarthritis of the Knee (2008)
  1. A4091012 A Phase 3, Randomized, Double-Blind, Multidose, Active and Placebo Controlled, Multicenter, Parallel Group Study of the Analgesic Effects of XXXX in Adult Patients with Chronic Low Back Pain (2009)
  1. A4091014 A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter Study of the Analgesic Efficacy and Safety of XXXX in Patients with Osteoarthritis of the Hip (2008)
  1. A4091016 A Phase 3, Multicenter, Randomized, Long Term Study of the Safety of XXXX in Patients with Osteoarthritis of the Knee of Hip (2009)
  1. A4091025 A Phase 3, Multicenter, Randomized, Double-Blind, Non-steroidal Anti-inflammatory Drug (XXXX)-Controlled Study of the Long Term Analgesic Efficacy and Safety of XXXX in Patients with Osteoarthritis of the Knee or Hip (2009)
  1. A4091039 A Phase 3, Randomized Double-Blind, Multidose, Active Controlled, Multicenter, Parallel Group Study of the Analgesic Effects of XXXX in Patients with Osteoarthritis of the Hip or Knee (2009)
  1. EFC10571 (SAVE-KNEE) A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of XXXX with XXXX for the Prevention of Venus Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery (2009)
  1. A4091040 A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study of XXXX in Patients with Osteoarthritis of the Knee or Hip
  1. EFC10342 (SAVE-HIP) A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery (2009)
  1. A4091003 A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of XXXX as Add-On Therapy to Opioid Medication in Patients with Pain Due To Bone Metastases (2009)
  1. A4091029 A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of XXXX as Add-On Therapy to Opioid Medication In Patients with Pain Due To Bone Metastases (2009)
  1. ACT11308 A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a Single Injection of XXXX on Reduction of Pain From Vertebral Fracture Associated with Osteoporosis (2009)
  1. ACT11286 A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a Single Injection of XXXX on Reduction of Pain from Chronic Pancreatitis (2009)
  1. A4091026 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of XXXX on Peripheral Nerve Function in Patients with Osteoarthritis (2010)
  1. SP904 A Multicenter, Open-label Extension Trial to Asses the Long-term Use of XXXX and Safety of XXXX and Adjunctive Therapy in Subjects with Partial-onset Seizures (2010)
  1. SP902 A Historical-controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXXX Monotherapy in Subjects with Partial-onset Seizures (2010)
  1. A4091040 A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study of XXXX in Patients with Osteoarthritis of the Knee or Hip (2010)
  1. INCB 18424-351 A randomized, double-blind, placebo controlled study of the XXXX inhibitor XXXX tablets administrated orally to subjects with primary myelofibrosis (PMF) , post Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) (2010)
  1. 102295 A Worldwide , Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of XXXX in Pediatric Migraineurs for the Treatment of Migraine with or without Aura (2010)
  1. 0462-082-00 A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of XXXX for the Acute Treatment of Migraine in Children and Adolescents (2010)
  1. CV185068 A Phase 3, Randomized, Double Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome
  1. ALO-01-10-4033 A Multi-center, Primary Care-Based, Open-Label, Study to Assess the Success of Converting Opioid Experienced Patients, with Chronic, Moderate to Severe pain to EMBEDA™ Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse And Diversion (2010)
  1. 75: A Phase IIIb, 24 week, Randomized, placebo-controlled, double-blinded, efficacy and safety study of XXXX in Black/African American patients With type 2 diabetes with a MTT sub-study (2010)
  1. SMR/0211OBD-1033 A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXXX in Subjects with Opioid-induced Bowel Dysfunction (2010)
  1. WEL-A-U306 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol® as Add-On to XXXX Therapy For Type 2 Diabetes Mellitus (2010)
  1. 09-OA-002 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (XXX) in Subjects with Osteoarthritis (OA) of the Knee (2010)
  1. H9B-MC-BCDM A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of XXXX in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response To Methotrexate Therapy (2011)
  1. H9B MC BCDO A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Safety and Efficacy of XXXX in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (2011)
  1. H9B MC BCDP A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy Of xxxx in Patients with Rheumatoid Arthritis (RA) (2011)
  1. H9B MC BCDV A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of XXXX in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had Inadequate Response To one or more TNF-α Inhibitors (2011)
  1. 10-OA-004 An Open Label, Safety Extension Study of Repeat Dosing with xxxx in Subjects with Osteoarthritis (OA) of the Knee
  1. 75 A Phase IIIb, 24-week, randomised, placebo-controlled, double-blinded, efficacy and safety study of XXXX in Black/African American patients with type 2 diabetes with a MTT sub-study
  1. TZP-101-CL-P008 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) XXXX Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
  1. RAS-RLS Safety and Efficacy of XXXX in Restless Legs Syndrome
  1. AS001 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled study to evaluate efficacy and safety of XXXX in subjects with active axial spondyloarthritis (axial spa)
  1. SMR/0211OBD-1003 A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXXX in Subjects with Opioid-induced Bowel Dysfuntion
  1. RA0056 A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study with an Active Comparator to Evaluate the Efficacy and Safety of XXXX Administered Subcutaneously for 12 Weeks to Subjects with Active Rheumatoid Arthritis Having Previously Failed TNF–Blocker Therapy
  1. RA0057 A Phase 2 Multi-Center, Open-Label, Follow-Up Study to Assess the Long-Term Safety and Efficacy of XXXX Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis who Completed Study RA0056
  1. TGC-09201 A Phase II Study to Determine the Efficacy and Safety of XXXX Expressing XXXX in Patients with Grade 3 Chronic Degenerative Joint Disease of the Knee
  1. CAIN457F2208: A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of XXXX in rheumatoid arthritis patients followed by an open label Extension
  1. D4300C00004 A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of XXXX Compared with XXXX in Patients with Active Rheumatoid Arthritis
  1. D4300C00005 A Long-term Extension Study to Assess the Safety and Efficacy of XXXX in the Treatment of Rheumatoid Arthritis
  1. A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous XXXX in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
  1. A phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of XXXX/ XXXX Insulin Inhalation Power Versus XXXX Inhalation Powder (Placebo) in Insulin Naive Subjects With Type 2 Diabetes Mellitus Poorly ;Controlled wit Oral Antidiabetic Agents Over a 24 Week Treatment Period
  1. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX in Subjects with Systemic Lupus Erythematosus (SLE)
  1. IAP309: A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the XXXX PCA System/15mcg to Intravenous Patient-Controlled Analgesia with Morphine for the Treatment of Acute Post-Operative Pain
  1. SAS115359: A Safety and Efficacy Study of Inhaled XXXX/XXXX versus Inhaled XXXX in the Treatment of Adolescent and Adult Subjects with Asthma
  1. HZC113782: A Clinical Outcomes Study to compare the effect of XXXX/XXXX 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease
  1. AUX-CC-870: A Phase 2a, Open-Label, Dose-Ranging Study of the Safety and Effectiveness of XXXX for the treatment of Adhesive Capsulitis of the Shoulder
  1. CC-10004-AS-001: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in the Treatment of Active Ankylosing Spondylitis
  1. 27018966IBS3001: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of XXXX in the Treatment of Patient With Diarrhea-Predominant Irritable Bowel Syndrome
  1. HYD3002: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of XXXX Tablets 20 to 120 mg Once-daily in Subjects with Moderate to Severe Chronic Low Back Pain
  1. ONU3704: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX/XXXX Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to XXXX Controlled-release Tablets (OXY) in Opioid-experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy
  1. X052160: A Phase 2 poof-of-concept study of XXXX in Active Inflammatory, Erosive Osteoarthritis of the Hand
  1. X052161: An Open-label Safety Extension Study of xxxx in Active Inflammatory, Erosive Osteoarthritis of the Hand
  1. An Open-Label Study to Evaluate the Safety of xxxx in Subjects with Painful Diabetic Neuropathy.
  1. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of xx mg QD, xmg BID of xxxx in Female Subjects with Severe Diarrhea-predominant IBS Who have Failed Conventional Therapy.
  1. A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of xxxx tablets 20 to 120 mg Once-daily in Subjects with moderate to Severe Chronic Low Back Pain
  1. A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a xxxx of Gel-One® for the Treatment of Osteoarthritis of the Knee with Open Label Safety Extension.
  1. TGC-B106727: Long-Term Safety Follow-Up of Study Subjects Who Were Previously Enrolled in a XXXX Clinical Trial and Were Administered XXXX –
  1. 189 Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral XXXX (110 mg or 150 mg, oral b.i.d) versus Acetylsalicylic Acid (100 mg oral q.d.) in Patients with Embolic Stroke of Undetermined Source (RESPECT ESUS) –
  1. SI 6603/1131 A Multicenter, Randomized, Double-blind, Controlled, Comparative Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)
  1. SI 6603/1132 A Multicenter: Open-Label Study of XXXX in Patients with Lumbar Disc Herniation (Phase III)
  1. KF7013-0 A Randomized, Double-blind Trial Investigating the Efficacy and Safety of Intravenous XXXX in Subjects with Complex Regional Pain Syndrome